Quoin Pharmaceuticals Files 8-K

TL;DR

QUOI filed an 8-K, details TBD.

AI Summary

Quoin Pharmaceuticals, Ltd. filed an 8-K on February 4, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or new developments, but it serves as a notification to the SEC.

Why It Matters

This 8-K filing indicates Quoin Pharmaceuticals, Ltd. has reported an event to the SEC, which could be material to investors, though the specific details are not yet disclosed in this filing.

Risk Assessment

Risk Level: medium — The filing is an 8-K, which typically reports material events, but the lack of specific details in this instance creates uncertainty.

Key Players & Entities

• Quoin Pharmaceuticals, Ltd. (company) — Filer of the 8-K report
• Cellect Biotechnology Ltd. (company) — Former company name
• Cellect Biomed Ltd. (company) — Former company name

FAQ

Filing Documents

• tm255460d1_8k.htm (8-K) — 27KB
• 0001104659-25-009137.txt ( ) — 196KB
• qnrx-20250204.xsd (EX-101.SCH) — 3KB
• qnrx-20250204_lab.xml (EX-101.LAB) — 33KB
• qnrx-20250204_pre.xml (EX-101.PRE) — 22KB
• tm255460d1_8k_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. Launch of Netherton Now Campaign Quoin Pharmaceuticals Ltd. (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced on February 4, 2025 that it has launched the "NETHERTON NOW" campaign to shed light on the profound and poorly understood impacts of Netherton Syndrome, a devastating genetic disease that has been significantly misdiagnosed in the past. It is estimated that up to 20% of babies born with Netherton Syndrome do not survive, highlighting the urgent need for greater awareness and new treatment options. Netherton Syndrome patients suffer from excess skin shedding as well as red, scaly skin that can cause painful itching and severe infections that can potentially lead to hospitalization, asthma, allergies and possibly skin cancer. They are also susceptible to water loss through the skin's surface and are always at risk of dehydration. This chronic condition severely impacts every aspect of life for patients and their families, yet it remains inadequately understood and poorly addressed by current treatment options. Currently, Quoin is conducting four ongoing clinical studies evaluating the safety and efficacy of QRX003 in Netherton Syndrome patients. Recently announced clinical data by Quoin has underscored the product's potential efficacy as a treatment for the disease. Quoin has also released photographic evidence highlighting the dramatic change in a patient's skin after 12 weeks of dosing with QRX003. The NETHERTON NOW website is intended to serve as a comprehensive resource hub, providing a platform for patients and families to share experiences and build connections, while also offering educational materials and updates on research advancements to raise public awareness about Netherton Syndrome. Information contained on or accessible through the website nethertonnow.com is not incorporated by reference in, or otherwise a part of, this Current Report on

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Date: February 4, 2025 QUOIN PHARMACEUTICALS LTD. By: /s/ Michael Myers Name: Dr. Michael Myers Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR